Kornitzer Capital Management Inc. KS increased its position in OptiNose Inc (NASDAQ:OPTN) by 12.2% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 554,035 shares of the company’s stock after purchasing an additional 60,175 shares during the period. Kornitzer Capital Management Inc. KS owned 1.34% of OptiNose worth $3,923,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the stock. BNP Paribas Arbitrage SA raised its position in shares of OptiNose by 1,569.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,006 shares of the company’s stock valued at $41,000 after buying an additional 3,766 shares in the last quarter. Stifel Financial Corp bought a new stake in shares of OptiNose during the 4th quarter worth about $63,000. Two Sigma Advisers LP bought a new stake in shares of OptiNose during the 4th quarter worth about $135,000. Bank of America Corp DE boosted its holdings in shares of OptiNose by 31.9% during the 4th quarter. Bank of America Corp DE now owns 53,593 shares of the company’s stock worth $332,000 after buying an additional 12,961 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of OptiNose by 29.2% during the 4th quarter. Geode Capital Management LLC now owns 203,308 shares of the company’s stock worth $1,260,000 after buying an additional 45,895 shares during the period. Institutional investors and hedge funds own 63.78% of the company’s stock.
Shares of NASDAQ:OPTN opened at $6.10 on Friday. The firm has a 50 day moving average of $6.25 and a 200-day moving average of $7.98. The stock has a market capitalization of $249.47 million, a PE ratio of -2.28 and a beta of 0.90. The company has a current ratio of 6.60, a quick ratio of 6.74 and a debt-to-equity ratio of 1.06. OptiNose Inc has a 12 month low of $4.44 and a 12 month high of $15.73.
OptiNose (NASDAQ:OPTN) last issued its earnings results on Monday, August 12th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09. OptiNose had a negative net margin of 670.20% and a negative return on equity of 102.10%. The company had revenue of $6.68 million during the quarter, compared to analysts’ expectations of $7.74 million. On average, research analysts predict that OptiNose Inc will post -2.81 EPS for the current fiscal year.
Several analysts have weighed in on OPTN shares. Zacks Investment Research cut shares of OptiNose from a “buy” rating to a “hold” rating in a research note on Thursday, July 11th. Piper Jaffray Companies set a $29.00 price objective on shares of OptiNose and gave the stock a “buy” rating in a research note on Tuesday, April 23rd. Royal Bank of Canada set a $20.00 price objective on shares of OptiNose and gave the stock a “buy” rating in a research note on Monday. BMO Capital Markets dropped their price objective on shares of OptiNose from $26.00 to $24.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $27.00 price objective on shares of OptiNose in a research note on Thursday, May 9th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $21.50.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Recommended Story: What is intrinsic value?
Want to see what other hedge funds are holding OPTN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptiNose Inc (NASDAQ:OPTN).
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.